NO315472B1 - Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk - Google Patents

Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk Download PDF

Info

Publication number
NO315472B1
NO315472B1 NO19934777A NO934777A NO315472B1 NO 315472 B1 NO315472 B1 NO 315472B1 NO 19934777 A NO19934777 A NO 19934777A NO 934777 A NO934777 A NO 934777A NO 315472 B1 NO315472 B1 NO 315472B1
Authority
NO
Norway
Prior art keywords
antibody
monoclonal antibody
cell line
cells
antigen
Prior art date
Application number
NO19934777A
Other languages
English (en)
Norwegian (no)
Other versions
NO934777L (no
NO934777D0 (no
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO934777D0 publication Critical patent/NO934777D0/no
Publication of NO934777L publication Critical patent/NO934777L/no
Publication of NO315472B1 publication Critical patent/NO315472B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19934777A 1991-07-03 1993-12-22 Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk NO315472B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
PCT/SE1992/000502 WO1993001303A1 (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line

Publications (3)

Publication Number Publication Date
NO934777D0 NO934777D0 (no) 1993-12-22
NO934777L NO934777L (no) 1994-02-11
NO315472B1 true NO315472B1 (no) 2003-09-08

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19934777A NO315472B1 (no) 1991-07-03 1993-12-22 Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk

Country Status (19)

Country Link
US (1) US5552293A (https=)
EP (1) EP0521842B1 (https=)
JP (1) JP3194020B2 (https=)
KR (1) KR100246681B1 (https=)
AT (1) ATE171193T1 (https=)
AU (2) AU658198B2 (https=)
CA (1) CA2073124C (https=)
DE (1) DE69226990T2 (https=)
DK (1) DK0521842T3 (https=)
EE (1) EE03031B1 (https=)
ES (1) ES2124250T3 (https=)
FI (1) FI109207B (https=)
HU (2) HU218084B (https=)
IE (1) IE80841B1 (https=)
IL (1) IL102390A (https=)
NO (1) NO315472B1 (https=)
NZ (1) NZ243435A (https=)
SE (1) SE9102074D0 (https=)
WO (2) WO1993001302A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ES2619313T3 (es) 2001-03-15 2017-06-26 Precision Biologics, Inc. Terapia de anticuerpos monoclonales para el cáncer de páncreas
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
WO2004004639A2 (en) * 2002-07-02 2004-01-15 Smithkline Beecham Corporation A novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL3524611T3 (pl) 2003-05-20 2021-06-14 Immunogen, Inc. Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
CA2597407C (en) * 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
BRPI1010620B8 (pt) 2009-06-03 2021-05-25 Immunogen Inc métodos de conjugação
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
SG11201806478PA (en) 2016-02-05 2018-08-30 Immunogen Inc Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
WO2019035034A1 (en) * 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
DK0610179T3 (da) * 1990-07-20 1997-03-24 Pharmacia & Upjohn Ab Målspecifikke antistof-superantigenkonjugater og fremstilling deraf

Also Published As

Publication number Publication date
US5552293A (en) 1996-09-03
IE922188A1 (en) 1993-01-13
WO1993001302A1 (en) 1993-01-21
JP3194020B2 (ja) 2001-07-30
IL102390A (en) 1996-01-19
DE69226990D1 (de) 1998-10-22
CA2073124A1 (en) 1993-01-04
EP0521842A2 (en) 1993-01-07
KR100246681B1 (ko) 2000-04-01
EE03031B1 (et) 1997-08-15
HU218084B (hu) 2000-05-28
NO934777L (no) 1994-02-11
DK0521842T3 (da) 1999-06-14
HUT71193A (en) 1995-11-28
NZ243435A (en) 1994-10-26
JPH05276987A (ja) 1993-10-26
FI935970A0 (fi) 1993-12-31
IL102390A0 (en) 1993-01-14
SE9102074D0 (sv) 1991-07-03
WO1993001303A1 (en) 1993-01-21
NO934777D0 (no) 1993-12-22
ATE171193T1 (de) 1998-10-15
FI935970L (fi) 1993-12-31
EP0521842B1 (en) 1998-09-16
AU658198B2 (en) 1995-04-06
HU9400011D0 (en) 1994-05-30
IE80841B1 (en) 1999-03-24
DE69226990T2 (de) 1999-03-25
AU2292092A (en) 1993-02-11
CA2073124C (en) 2007-06-19
HU211512A9 (en) 1995-11-28
FI109207B (fi) 2002-06-14
AU1942592A (en) 1993-01-07
EP0521842A3 (https=) 1994-01-26
ES2124250T3 (es) 1999-02-01

Similar Documents

Publication Publication Date Title
NO315472B1 (no) Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk
CN113544156B (zh) 抗Claudin18.2抗体及其应用
JP4414142B2 (ja) 特異的結合タンパク質およびその使用
CA2250080C (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP0721470B1 (en) Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
RU2266298C2 (ru) Антитела к антигену эпителиальных опухолей желудочно-кишечного тракта человека, родственному альфа 6 бета 4 интегрину
US20100240100A1 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
WO1997034636A9 (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
CN1551783B (zh) 类K121抗体在制备用于治疗κ类型多发性骨髓瘤的药物中的应用
US6787638B1 (en) Tumor specific human monoclonal antibodies and methods of use
CN113597432B (zh) 抗EpCAM抗体及其应用
JPH09183799A (ja) ヒト化モノクローナル抗体